Anika's CINGAL cleared in Canada for OA of the knee

• Health Canada approves Anika Therapeutics' (ANIK +0.5%) CINGAL (hyaluronic acid plus triamcinolone hexacetonide) for the treatment of symptoms of osteoarthritis (OA) of the knee. This is the first clearance for the company's next-generation viscosupplement.
• CINGAL combines the lubricant hyaluronic acid with a steroid (triamcinolone hexacetonide) to treat inflammation.